Zogenix Inc. (Nasdaq: ZGNX)

https://www.zogenix.com

Zogenix, Inc. is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency. *

	Start	2008-01-12 existent
	Group	UCB (Group)
	Industry	CNS drug (neurological drug)
	Industry 2	DRUGS, ORPHAN
	Person	Farr, Stephen J. (Zogenix 202201 CEO)

	Region	Emeryville, CA
	Country	United States (USA)
	Street	5959 Horton Street
	City	94608 Emeryville, CA
	Tel	+1-858-259-1165
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Zogenix, Inc.. (3/6/20). "Press Release: Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares". Emeryville, CA.

		Record changed: 2023-07-10